113 related articles for article (PubMed ID: 25509985)
1. An AF9/ENL-targted peptide with therapeutic potential in mixed lineage leukemias.
Barretto NN; Karahalios DS; You D; Hemenway CS
J Exp Ther Oncol; 2014; 10(4):293-300. PubMed ID: 25509985
[TBL] [Abstract][Full Text] [Related]
2. Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia.
Okuda H; Stanojevic B; Kanai A; Kawamura T; Takahashi S; Matsui H; Takaori-Kondo A; Yokoyama A
J Clin Invest; 2017 May; 127(5):1918-1931. PubMed ID: 28394257
[TBL] [Abstract][Full Text] [Related]
3. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes.
Biswas D; Milne TA; Basrur V; Kim J; Elenitoba-Johnson KS; Allis CD; Roeder RG
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15751-6. PubMed ID: 21896721
[TBL] [Abstract][Full Text] [Related]
4. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.
Shen C; Jo SY; Liao C; Hess JL; Nikolovska-Coleska Z
J Biol Chem; 2013 Oct; 288(42):30585-30596. PubMed ID: 23996074
[TBL] [Abstract][Full Text] [Related]
5. Collaboration of MLLT1/ENL, Polycomb and ATM for transcription and genome integrity.
Ui A; Yasui A
Nucleus; 2016 Apr; 7(2):138-45. PubMed ID: 27310306
[TBL] [Abstract][Full Text] [Related]
6. The synthetic peptide PFWT disrupts AF4-AF9 protein complexes and induces apoptosis in t(4;11) leukemia cells.
Srinivasan RS; Nesbit JB; Marrero L; Erfurth F; LaRussa VF; Hemenway CS
Leukemia; 2004 Aug; 18(8):1364-72. PubMed ID: 15269783
[TBL] [Abstract][Full Text] [Related]
7. Development of a high-throughput screening-compatible assay for the discovery of inhibitors of the AF4-AF9 interaction using AlphaScreen technology.
Watson VG; Drake KM; Peng Y; Napper AD
Assay Drug Dev Technol; 2013 May; 11(4):253-68. PubMed ID: 23679849
[TBL] [Abstract][Full Text] [Related]
8. Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth.
Wu F; Nie S; Yao Y; Huo T; Li X; Wu X; Zhao J; Lin YL; Zhang Y; Mo Q; Song Y
Theranostics; 2021; 11(17):8172-8184. PubMed ID: 34373735
[TBL] [Abstract][Full Text] [Related]
9. AF4 and AF4-MLL mediate transcriptional elongation of 5-lipoxygenase mRNA by 1, 25-dihydroxyvitamin D3.
Ahmad K; Scholz B; Capelo R; Schweighöfer I; Kahnt AS; Marschalek R; Steinhilber D
Oncotarget; 2015 Sep; 6(28):25784-800. PubMed ID: 26329759
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between 14-3-3θ and AF4 enhances MLL-AF4 activity and promotes leukemia cell proliferation.
Fioretti T; Cevenini A; Zanobio M; Raia M; Sarnataro D; Salvatore F; Esposito G
Cell Oncol (Dordr); 2019 Dec; 42(6):829-845. PubMed ID: 31493143
[TBL] [Abstract][Full Text] [Related]
11. The YEATS domain epigenetic reader proteins ENL and AF9 and their therapeutic value in leukemia.
Hu H; Muntean AG
Exp Hematol; 2023 Aug; 124():15-21. PubMed ID: 37295550
[TBL] [Abstract][Full Text] [Related]
12. Human Polymerase-Associated Factor complex (PAFc) connects the Super Elongation Complex (SEC) to RNA polymerase II on chromatin.
He N; Chan CK; Sobhian B; Chou S; Xue Y; Liu M; Alber T; Benkirane M; Zhou Q
Proc Natl Acad Sci U S A; 2011 Sep; 108(36):E636-45. PubMed ID: 21873227
[TBL] [Abstract][Full Text] [Related]
13. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription.
Yokoyama A; Lin M; Naresh A; Kitabayashi I; Cleary ML
Cancer Cell; 2010 Feb; 17(2):198-212. PubMed ID: 20153263
[TBL] [Abstract][Full Text] [Related]
14. MLL fusion partners AF4 and AF9 interact at subnuclear foci.
Erfurth F; Hemenway CS; de Erkenez AC; Domer PH
Leukemia; 2004 Jan; 18(1):92-102. PubMed ID: 14603337
[TBL] [Abstract][Full Text] [Related]
15. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling.
Bitoun E; Oliver PL; Davies KE
Hum Mol Genet; 2007 Jan; 16(1):92-106. PubMed ID: 17135274
[TBL] [Abstract][Full Text] [Related]
16. Taking MLL through the MudPIT: identification of novel complexes that bring together MLL-fusion proteins and transcription elongation factors.
Fromm G; Adelman K
Mol Cell; 2010 Feb; 37(4):449-50. PubMed ID: 20188661
[TBL] [Abstract][Full Text] [Related]
17. Transcription control by the ENL YEATS domain in acute leukaemia.
Erb MA; Scott TG; Li BE; Xie H; Paulk J; Seo HS; Souza A; Roberts JM; Dastjerdi S; Buckley DL; Sanjana NE; Shalem O; Nabet B; Zeid R; Offei-Addo NK; Dhe-Paganon S; Zhang F; Orkin SH; Winter GE; Bradner JE
Nature; 2017 Mar; 543(7644):270-274. PubMed ID: 28241139
[TBL] [Abstract][Full Text] [Related]
18. Ligand-independent FLT3 activation does not cooperate with MLL-AF4 to immortalize/transform cord blood CD34+ cells.
Montes R; Ayllón V; Prieto C; Bursen A; Prelle C; Romero-Moya D; Real PJ; Navarro-Montero O; Chillón C; Marschalek R; Bueno C; Menendez P
Leukemia; 2014 Mar; 28(3):666-74. PubMed ID: 24240202
[TBL] [Abstract][Full Text] [Related]
19. The mixed lineage leukemia (MLL) fusion-associated gene AF4 promotes CD133 transcription.
Mak AB; Nixon AM; Moffat J
Cancer Res; 2012 Apr; 72(8):1929-34. PubMed ID: 22337994
[TBL] [Abstract][Full Text] [Related]
20. Misguided transcriptional elongation causes mixed lineage leukemia.
Mueller D; García-Cuéllar MP; Bach C; Buhl S; Maethner E; Slany RK
PLoS Biol; 2009 Nov; 7(11):e1000249. PubMed ID: 19956800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
